A B S T R A C T Antihemophilic globulin (AHF, factor VIII) levels were measured by a standard coagulation assay and by an immunological technique before and serially after infusion of fresh frozen plasma or cryoprecipitate into patients with von Willebrand's disease. Initial levels of AHF, measured both as procoagulant and as antigen, were low. Immediately after transfusions, the rise in levels of AHF-like antigen was compatible with the quantity of antigen present in the infused plasma or cryoprecipitate. Thereafter, levels of antigen declined rapidly and reached preinfusion values in approximately 24 hr. In contrast, procoagulant activity remained elevated, and sometimes continued to rise, for longer periods of time. One possible explanation of this finding is that the AHF molecule produced by patients with von Willebrand's disease, in response to transfusion of as yet unidentified factors, lacks the antigenic site associated with the normal AHF molecule or the inactive molecule produced by patients with hemophilia A.
INTRODUCTION von Willebrand's disease is a familial hemorrhagic disorder characterized by an autosomal dominant mode of inheritance (2), a prolonged bleeding time (2) , reduced levels of plasma antihemophilic factor. (AHF, factor VIII)' (3) , and decreased platelet retention in glass bead columns (4) . It has been established recently, by means of a heterologous precipitating antibody to purified normal AHF, that the plasma of patients with classic sex-linked hemophilia A contains normal or increased concentrations of a molecule which precipitates with this antibody (5, 6) . The half-life of AHF-like antigen after infusion into hemophilic subjects is significantly longer than that of AHF procoagulant (i.e., clot-promoting) activity suggesting that utilization of the antigenic material is in some way delayed in these patients (7) . The plasma of patients with von Willebrand's disease contains reduced quantities of antigen (6) . Infusion of plasma or plasma concentrates results in a delayed rise in the AHF clot-promoting activity in the blood of patients with von Willebrand's disease (3, 8) . The xnagnitude and duration of this response is compatible with the production, in vivo, of functionally active AHF. We report here studies of changes in the levels of AHF clotpromoting activity and AHF-like antigen after infusions of fresh frozen plasma or cryoprecipitate into patients with von Willebrand's disease. Unexpectedly, the delayed 'Abbre2sation used in this paper: AHF, antihemophilic factor.
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METHODS
The methods for assay of AHF clot-promoting activity, for purification of AHF from normal people, preparation of an antiserum to this, and the characteristics of the antiserum have been described in the accompanying paper (7) and previously (6) . The method for the quantitation of AHF-like antigen employed in this study employed the application of concentrates of plasma to the wells of the antibody-containing agarose slides (6) : this was necessary because the patients here studied had initial levels of AHF-like antigeni too low to be detected by application of unconceiitrated plasmiia to the wells.
Collection of blood samples and preparationi of plasmiia was as previously described (6) with the exception that blood from the patients treated with fresh frozen plasma was mixed with one-ninth volume of 3.8% sodium citrate. The difference in the anticoagulants reflects the different choice of anticoagulant in our respective laboratories.
1 U of AHF clot-promoting activity is that amount present in 1 ml of pooled whole normal plasma (6) . 1 U of AHFlike antigen is also the amount present in 1 ml pooled whole normal plasma (6) . It must be emphasized that the two techniques do not necessarily measure identical molecular entities, so the two unitages need not necessarily be interchangeable.
Patients with a diagnosis of von Willeb tablished on a basis of typical family and of bleeding disorder, reduced levels of pl promoting activity, and in most cases, a longed bleeding time were hospitalized fc variety of bleeding episodes or, in one c; of mammary carcinoma. All patients were f received several transfusions of plasma ( previously with the exception of the pati of cryoprecipitate. Qualitatively similar results were observed in a second patient treated with fresh frozen plasma. Fig. 2 illustrates the observations made before and after infusion of 225 h of fresh frozen ml fresh frozen plasma into the patient illustrated in in one of these. Fig. 1 finding. As in the cases treated with fresh frozen plasma, antigen levels declined rapidly to reach approximately preinfusion values in 24 hr, while the level of AHF clotpromoting activity remained significantly elevated between 48 and 72 hr. It should be pointed out that in this patient, in contrast to those treated with fresh frozen plasma, the infused material contained a large amount of AHF clot-promoting activity which is represented by the large increase evident in the first postinfusion observation; this immediate large rise tends to obscure the delayed rise in AHF clot-promoting activity typical of von Willebrand's disease which is represented here by the elevated levels noted at 40 and 72 hr. Results qualitatively similar to these were observed in three further patients treated with cryoprecipitate infusions. DISCUSSION Zimmerman, Ratnoff, and Powell (6) using quantitative i,mmunoelectrophoresis, showed that patients with von Willebrand's disease had reduced levels of AHF-like antigen, while plasma of patients with classic hemophilia contained normal quantities of AHF-like antigen. Earlier studies, which employed a variety of antibody preparations, had produced less clear-cut results (9-11), but several groups have now confirmed this finding (12) (13) (14) (15) .
Earlier studies from this laboratory, which showed correlation of levels of AHF antigen and clotting activity in normal people and, at reduced levels, in those with von Willebrand's disease (6), were carried out in unstressed subjects. Recent studies indicate that normal people stressed by strenuous exercise respond with a parallel rise in AHF clot-promoting activity and antigen (16, 17) , as do some patients undergoing the stress of pneumoencephalography (17) . Normal pregnancy is also associated with a parallel rise in levels of antigen and clotting activity (17) . These observations, together with the finding that highly purified preparations of AHF from normal plasma possess both antigen and clot-promoting activity (6) , suggest that the sites determining these activities are carried on the same or closely similar molecules, or that a relatively fixed proportion of the material detected as antigen in normal plasma has functional clot-promoting activity.
The divergence of levels of AHF clot-promoting activity and AHF-like antigen after transfusion of patients with von Willebrand's disease contrasts sharply with that observed in classic hemophilia (7), and necessitates a different consideration of their role in the AHF "economy" of patients with the disorder. The very rapid disappearance of the antigen from the blood of patients with von Willebrand's disease suggests that these people are capable of metabolizing or destroying antigen in a manner not available to hemophiliacs. This, together with the subsequent increase in AHF clotting activity might suggest that antigen is present on a precursor molecule which patients with von Willebrand's disease produce in reduced quantities but can convert to an agent with AHF clotting activity once it is supplied to them. The relationship of this material to the functional AHF of normal subjects is difficult to determine at present as the material produced after transfusion by von Willebrand's disease subjects is not associated with antigen, detectable with the antiserum we used, whereas in normal people AHF clotting activity and antigen appear closely associated as indicated by the observations detailed above.
Possible interpretations of the available data on AHF in normals, hemophiliacs and those with von Willebrand's disease may be summarized as follows:
(a) The antigen detected by the rabbit antiserum appears only on a precursor of the AHF clot-promoting agent. This is suggested by the observations reported here on von Willebrand's disease, and the observations on the effect of infusion of cryoprecipitate into hemophiliacs (7) are compatible with this concept. However there is at present no direct evidence that, in normal plasma, the AHF clot-promoting activity and the antigen are separable entities. The reverse is suggested by the fact that the antiserum to normal purified AHF destroys functional AHF clot-promoting activity, and studies in progress, but as yet incomplete, indicate that the antiserum to the nonfunctional material purified froxn hemophilic plasma similarly destroys the clot-promoting activity of normal AHF; both these observations suggest that the antigenic site and that determining clot-promoting activity appear on the same molecule or on two species of molecule both of which are essential for the expression of AHF clotpromoting activity.
( purified AHF from normal subjects (whiclh contains the antigen) and the material prepared in an identical manner from hemophilic plasma (devoid of clotting activity but also containing the antigen) will correct, in vitro, the defective adhesiveness of platelets from patients with von Willebrand's disease (18) . It is established that infusions of normal plasma or serum or plasma from hemophilic subjects (all of which contain the antigen) will correct the defect in platelet adhesiveness and the bleeding time in patients with von Willebrand's disease, but this effect lasts for only a few hours (3, 8, 19) , whereas the patient shows increased or increasing levels of AHF clot-promoting activity for longer periods. Our observation that this clot-promoting activity is not associated with AHF-like antigen and that infused antigen is cleared from the circulation in a period comparable with that for which the bleeding time and platelet adhesiveness are corrected, supports the suggestion that the antigenic material corrects the abnormality in platelet function in von Willebrand's disease (18) , whether AHF clot-promloting activity is present or not.
Although the precise nature and the abnormalities of the molecules produced by patients with von \Villebrand's disease and classic hemophilia are not yet clear, the dlata available suggest that von Willebrand's disease may be due to a defect or a deficiency of a single protein; tlhis, when infused into patients, corrects the bleeding time by restoring adhesiveness to platelets while it remains in the circulation, and stimulates, in a manner as yet undefined, production of an AHF molecule which has functional activitv but lacks an antigenic site normally associate(I w ith AHF.
